Cargando…
Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease
BACKGROUND: Enkephalins of the opioid system exert several cardiorenal effects. Proenkephalin (PENK), a stable surrogate, is associated with heart failure (HF) development after myocardial infarction and worse cardiorenal function and prognosis in patients with HF. The association between plasma PEN...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715404/ https://www.ncbi.nlm.nih.gov/pubmed/34716603 http://dx.doi.org/10.1002/clc.23729 |
_version_ | 1784624120226381824 |
---|---|
author | Emmens, Johanna E. ter Maaten, Jozine M. Brouwers, Frank P. Kieneker, Lyanne M. Damman, Kevin Hartmann, Oliver Schulte, Janin Bakker, Stephan J. L. de Boer, Rudolf A. Voors, Adriaan A. |
author_facet | Emmens, Johanna E. ter Maaten, Jozine M. Brouwers, Frank P. Kieneker, Lyanne M. Damman, Kevin Hartmann, Oliver Schulte, Janin Bakker, Stephan J. L. de Boer, Rudolf A. Voors, Adriaan A. |
author_sort | Emmens, Johanna E. |
collection | PubMed |
description | BACKGROUND: Enkephalins of the opioid system exert several cardiorenal effects. Proenkephalin (PENK), a stable surrogate, is associated with heart failure (HF) development after myocardial infarction and worse cardiorenal function and prognosis in patients with HF. The association between plasma PENK concentrations and new‐onset HF in the general population remains to be established. HYPOTHESIS: We hypothesized that plasma PENK concentrations are associated with new‐onset HF in the general population. METHODS: We included 6677 participants from the prevention of renal and vascular end‐stage disease study and investigated determinants of PENK concentrations and their association with new‐onset HF (both reduced [HFrEF] and preserved ejection fraction [HFpEF]). RESULTS: Median PENK concentrations were 52.7 (45.1–61.9) pmol/L. Higher PENK concentrations were associated with poorer renal function and higher NT‐proBNP concentrations. The main determinants of higher PENK concentrations were lower estimated glomerular filtration rate (eGFR), lower urinary creatinine excretion, and lower body mass index (all p < .001). After a median 8.3 (7.8–8.8) years follow‐up, 221 participants developed HF; 127 HFrEF and 94 HFpEF. PENK concentrations were higher in subjects who developed HF compared with those who did not, 56.2 (45.2–67.6) versus 52.7 (45.1–61.6) pmol/L, respectively (p = .003). In competing‐risk analyses, higher PENK concentrations were associated with higher risk of new‐onset HF (hazard ratio [HR] = 2.09[1.47–2.97], p < .001), including both HFrEF (HR = 2.31[1.48–3.61], p < .001) and HFpEF (HR = 1.74[1.02–2.96], p = .042). These associations were, however, lost after adjustment for eGFR. CONCLUSIONS: In the general population, higher PENK concentrations were associated with lower eGFR and higher NT‐proBNP concentrations. Higher PENK concentrations were not independently associated with new‐onset HFrEF and HFpEF and mainly confounded by eGFR. |
format | Online Article Text |
id | pubmed-8715404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wiley Periodicals, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87154042022-01-06 Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease Emmens, Johanna E. ter Maaten, Jozine M. Brouwers, Frank P. Kieneker, Lyanne M. Damman, Kevin Hartmann, Oliver Schulte, Janin Bakker, Stephan J. L. de Boer, Rudolf A. Voors, Adriaan A. Clin Cardiol Clinical Investigations BACKGROUND: Enkephalins of the opioid system exert several cardiorenal effects. Proenkephalin (PENK), a stable surrogate, is associated with heart failure (HF) development after myocardial infarction and worse cardiorenal function and prognosis in patients with HF. The association between plasma PENK concentrations and new‐onset HF in the general population remains to be established. HYPOTHESIS: We hypothesized that plasma PENK concentrations are associated with new‐onset HF in the general population. METHODS: We included 6677 participants from the prevention of renal and vascular end‐stage disease study and investigated determinants of PENK concentrations and their association with new‐onset HF (both reduced [HFrEF] and preserved ejection fraction [HFpEF]). RESULTS: Median PENK concentrations were 52.7 (45.1–61.9) pmol/L. Higher PENK concentrations were associated with poorer renal function and higher NT‐proBNP concentrations. The main determinants of higher PENK concentrations were lower estimated glomerular filtration rate (eGFR), lower urinary creatinine excretion, and lower body mass index (all p < .001). After a median 8.3 (7.8–8.8) years follow‐up, 221 participants developed HF; 127 HFrEF and 94 HFpEF. PENK concentrations were higher in subjects who developed HF compared with those who did not, 56.2 (45.2–67.6) versus 52.7 (45.1–61.6) pmol/L, respectively (p = .003). In competing‐risk analyses, higher PENK concentrations were associated with higher risk of new‐onset HF (hazard ratio [HR] = 2.09[1.47–2.97], p < .001), including both HFrEF (HR = 2.31[1.48–3.61], p < .001) and HFpEF (HR = 1.74[1.02–2.96], p = .042). These associations were, however, lost after adjustment for eGFR. CONCLUSIONS: In the general population, higher PENK concentrations were associated with lower eGFR and higher NT‐proBNP concentrations. Higher PENK concentrations were not independently associated with new‐onset HFrEF and HFpEF and mainly confounded by eGFR. Wiley Periodicals, Inc. 2021-10-30 /pmc/articles/PMC8715404/ /pubmed/34716603 http://dx.doi.org/10.1002/clc.23729 Text en © 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Investigations Emmens, Johanna E. ter Maaten, Jozine M. Brouwers, Frank P. Kieneker, Lyanne M. Damman, Kevin Hartmann, Oliver Schulte, Janin Bakker, Stephan J. L. de Boer, Rudolf A. Voors, Adriaan A. Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease |
title | Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease |
title_full | Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease |
title_fullStr | Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease |
title_full_unstemmed | Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease |
title_short | Proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease |
title_sort | proenkephalin and the risk of new‐onset heart failure: data from prevention of renal and vascular end‐stage disease |
topic | Clinical Investigations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715404/ https://www.ncbi.nlm.nih.gov/pubmed/34716603 http://dx.doi.org/10.1002/clc.23729 |
work_keys_str_mv | AT emmensjohannae proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT termaatenjozinem proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT brouwersfrankp proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT kienekerlyannem proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT dammankevin proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT hartmannoliver proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT schultejanin proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT bakkerstephanjl proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT deboerrudolfa proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease AT voorsadriaana proenkephalinandtheriskofnewonsetheartfailuredatafrompreventionofrenalandvascularendstagedisease |